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Clinical Relations of Sarcopenia
IGP Suka Aryana
Abstract
Sarcopenia is one of geriatric syndromes, characterized by decreased muscle 
mass accompanied by decreased muscle strength and/or performance. It is more 
prevalent with increase in age, and the prevalence depends on the criteria applied 
and the characteristic of the elderly. Sarcopenia has a higher risk of morbidity and 
mortality in elderly patients. The definition criteria of sarcopenia are still contro-
versial, but diagnostic criteria from the Asian Working Group for Sarcopenia and 
the European Working Group on Sarcopenia in Older People (EWGSOP) are the 
most used criteria for clinical practice. Pathogenesis sarcopenia involved a mul-
tifactorial process and is divided into intrinsic and extrinsic factors. Risk factors 
for sarcopenia include constitutional factors, aging, lifestyle, changes in body 
condition, and chronic diseases. Based on that, sarcopenia is divided into primary 
and secondary sarcopenia. There are three stage of sarcopenia, which are pre-
sarcopenia, sarcopenia, and severe sarcopenia. Nutrition and exercise are the two 
main pillars to manage sarcopenia.
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1. Introduction
The consequences of sarcopenia due to aging are often not getting noticed. 
Sarcopenia, which is characterized by decreased muscle mass accompanied by 
decreased muscle strength and/or performance, is often regarded as an ordinary 
physiological change due to aging. Muscles that have a mass of nearly 50% of the 
body mass are very important because besides serving as a body movement tool, 
they also are endocrine organs (secrete proteins called myokines that affect the 
metabolism of bodies systematically) and protective organs (counteract the nega-
tive effects of body fat). If muscle mass decreases, then the protective function of 
the body will be disrupted.
As age increases, the prevalence of sarcopenia also increases, where at an age 
of 65–70 years, the prevalence is between 13 and 24%, and at the age of more than 
80 years, it is more than 50% [1]. The prevalence of sarcopenia based on gender at 
the age of 60–69 years is found in 10% of men and 8% of women, while in those 
over 80 years, it is in 40% of men and 18% of women [2]. The prevalence also differs 
based on the health-care setting. In acute care hospitals (age > 65 years), the preva-
lence is 10%. In long-term care facilities (age > 70 years), it is 33%, and in commu-
nity-dwelling elderly (age ≥ 60 years), it is 29% [3]. It is difficult to obtain the typical 
prevalence of sarcopenia because it depends on the definition applied and character-
istics of the elderly, but in the results from large-scale studies involving 1000 or more 
participants, the prevalence rate is estimated to be between 6 and 12% [4].
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Sarcopenia is a risk factor for adverse outcomes in the elderly, including frailty, 
fractures, falls, and mortality. Sarcopenic elderly patients have a higher risk of 
cardiovascular death, especially patients with obesity. In cancer patients, sarcopenia 
reduces the survival rate [4, 5]. Sarcopenia is also associated with a large health 
expenditure which, in the USA (in 2000), is reported to be approximately $18.5 
billion ($10.8 billion for men and $7.7 billion for women) [6].
This chapter will discuss mainly about the clinical relations of sarcopenia as well 
as its definition, pathogenesis, risk factors, diagnosis, stage, and its management.
2. Definition and terminology of sarcopenia
Sarcopenia is a syndrome characterized by progressive, complete loss of mass, 
strength, and/or skeletal muscle performance that is at risk of causing physical 
disability, low quality of life, and death [7]. Based on the Asian Working Group for 
Sarcopenia (AWGS), elderly with low muscle mass coupled with low grip strength 
and/or low walking speed are diagnosed with sarcopenia [8]. The rationalization 
of the use of muscle mass and strength separately on sarcopenia criteria is because 
muscle strength does not depend solely on muscle mass and the relationship 
between strength and muscle mass is not linear. Therefore, defining sarcopenia only 
from muscle mass considered is to be narrow and of limited clinical value [9].
Another opinion states that there is another term for stating muscle assessment, 
dynapenia. Dynapenia can be defined as a syndrome of loss of muscle strength 
related to age but not caused by neurological or muscular disease. In determining 
the mechanism of dynapenia, it is different from the mechanism of sarcopenia. The 
incidence of sarcopenia is determined by multifactorals characterized by a decrease 
in muscle mass, strength, and/or performance, while dynapenia is determined by 
only one factor, namely muscle weakness.
Muscle weakness is one of the factors involved in the etiology of dynapenia 
which causes functional limitations or physical disabilities. The determination of 
dynapenia starts with screening individuals over 60 years of age. For groups with 
high risk, knee extension strength assessment should be carried out to establish the 
diagnosis of dynapenia, while in the low-risk group it is recommended to take grip 
strength assessment measurements to confirm the results of the previous screening. 
Nevertheless, sarcopenia is more widely studied and discussed than dynapenia [10].
3. Pathogenesis of sarcopenia
There are several mechanisms involved in the progression of sarcopenia 
(Figure 1). These mechanisms involve protein synthesis, proteolysis, neuromuscu-
lar integrity, and mobility of nutritional status. In individuals with sarcopenia, vari-
ous mechanisms may be involved and their contribution varies relative to time [7]. 
Walston also believes that there is a multifactorial process that triggers sarcopenia. 
These triggers include chronic illness, fat infiltration, physical inactivity, hormonal 
changes, energy, protein intake, oxidative stress, and inflammatory processes. The 
inflammatory process is recognized as a basic mechanism that results in the stimu-
lation of muscle protein catabolism [11].
When viewed from simpler pathogenesis, sarcopenia is divided into two 
factors, namely intrinsic and extrinsic factors. Intrinsic factors consist of 
accumulation of pro-inflammatory cytokines, oxidative stress, mitochondrial 
dysfunction, insulin resistance, and disorders of motor neuron endplates. While 
extrinsic factors consist of radiation, nutrition, drugs consumed, smoking 
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behavior, infection, social environment, and physical activity. The interaction of 
intrinsic and extrinsic factors occurs in a complex, simultaneous, and dynamic 
manner. Every elderly person who experiences sarcopenia will have specific 
and individual interactions. In the end, the condition occurs as an imbalance 
of protein metabolism between degradation/catabolism and protein synthesis/
anabolism. Sarcopenia occurs due to high protein catabolism accompanied by 
low protein anabolism [12]. High catabolism often results from chronic inflam-
mation in the elderly. The elderly experience an immunosenescence condition 
that causes chronic inflammatory conditions of a low degree. In this condition, 
the body will be exposed to long-term pro-inflammatory cytokine mediators. 
Pro-inflammatory cytokines such as TNF-α will trigger muscle cell apoptosis in 
the elderly [13]. While protein metabolism decreases due to decreased protein 
intake and physical activity as well as decreased IGF-1 and growth hormone due 
to the process.
4. Risk factors for sarcopenia
Sarcopenia is a geriatric syndrome that is influenced by various factors including 
the following [7].
4.1 Constitutional factor
Constitutional factors are factors that are inherently closely related to humans, 
such as age, sex, and genetics. Age affects the occurrence of sarcopenia. The 
prevalence of sarcopenia increases with age, and even more than 45% of people 
over 80 years of age experience sarcopenia [14]. Decreased estrogen levels during 
menopause can cause a decrease in bone density, muscle mass, and muscle strength. 
In this case, the hormonal role of menopause is related to sarcopenia [15]. A study 
of 1971 elderly people in Kashiwa City, Chiba, Japan, showed differences in the 
prevalence of sarcopenia by sex, where in men it was 14.2%, while in women it was 
22.1% [16]. Reverse results can be obtained elsewhere due to the differences in hab-
its, activities, and nutritional intake. Several genes are related to lower limb muscle 
strength such as the growth differentiation factor 8 (GDF8) gene, cyclin-dependent 
kinase inhibitor 1 A (CDKN1A), and myogenic differentiation antigen 1 (MYOD1). 
Besides that, ciliary neurotrophic factor gene variant (CNTF A allele) is associated 
with loss of muscle strength [17].
Figure 1. 
Mechanisms of sarcopenia [7]. Note: Growth hormone (GH); insulin-like growth factor 1 (IGF-1).
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4.2 Aging factor
The consequences of the aging process cause changes in the body system that 
is different for every human being. The aging process causes several changes in 
the human body system associated with sarcopenia, such as loss of neuromus-
cular function, changes in endocrine function, increased production of pro- 
inflammatory cytokines, and mitochondrial dysfunction. The aging process causes 
a decrease in the coordination of muscle work and a decrease in muscle strength 
due to a decrease in the number of alpha motor neurons and motor units. The 
aging process also results in atrophy of type II muscle fibers. Type II muscle fibers 
are found in large muscles that are important for basic activities such as getting 
up, going upstairs, and balance. Also, there is structural damage and decreased 
neuronal function at the motor center to the neuromuscular junction. Good muscle 
contraction requires the optimal functioning of the neuromuscular system because 
muscle tissue and nerve tissue are closely related to form motor neurons [18–20].
4.3 Lifestyle
The current lifestyle affects the incidence of sarcopenia in the elderly. Decreased 
food intake, especially protein, accompanied by less physical activity increases 
the risk of sarcopenia. Physical activity in the elderly experiences setbacks due to 
technological advancements such as elevators, escalators, vehicles, and others. Food 
consumption in the elderly is also changing, which tends to increase the consump-
tion of fast food that is high in calories and fat. Optimal nutrition, especially 
protein, is needed to maintain muscle mass. Geriatric patients require a minimum 
of 1.2–2.0 g of protein/kilogram of body weight per day [21].
4.4 Changes in body condition
Prolonged bed rest increases the risk of sarcopenia. This is due to the lack of 
physical activity and mobility; immobility and underweight increase the risk of 
sarcopenia due to increased protein catabolism.
4.5 Chronic disease
Chronic diseases such as diabetes, advanced organ failure, cognitive impair-
ment, and mood disorders cause chronic inflammation that can cause sarcopenia.
5. Diagnosis of sarcopenia
The diagnosis of sarcopenia is based on various risk factors reinforced by 
muscle weakness, fatigue, low endurance associated with decreased walking speed, 
impaired movement, and inability to perform daily tasks. The problem of diagnosis 
arises due to the variety of these sizes when viewed from age, race, and gender. 
There has not been much great research and precise accuracy to get a normal cutoff 
point. These sizes differ based on race and gender. Some researchers and research 
working groups also issued mixed figures.
Based on the European Working Group on Sarcopenia in Older People 
(EWGSOP), a criterion for sarcopenia is a loss of muscle mass coupled with one 
of the two conditions, namely loss of muscle strength and or loss of performance 
[7, 22]. In 2014, AWGS also issued a consensus with the same criteria with only 
changes in the size of the normal value. The other criteria for defining sarcopenia 
from the international society are listed in Table 1.
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Sarcopenia measurement parameters consist of measurements of muscle mass, 
muscle strength, and function or physical performance (physical performance). 
In clinical practice, diagnosis can follow the algorithm set by AWGS in 2014, as 
shown in Figure 2. The normal threshold check requirements are clearly explained 
in Table 2. Experts often experience differences of opinion for difficulty in getting 
a normal value or cutoff and determining the best inspection technique to get the 
most accurate results.
5.1 Muscle mass
Measurement of muscle mass can be done by using computed tomography 
(CT), magnetic resonance imaging (MRI), and dual energy X-ray absorptiometry 
(DXA). The use of CT and MRI in muscle mass measurement is the measurement 
method that has the best accuracy because the measurement can distinguish fatty 
tissue from other soft tissues, but this measurement requires expensive costs [27]. 
Other measurements using DXA can provide results of body fat composition, bone 
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test) or reduced 
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Reduced muscle mass 
(appendicular lean 
mass relative to height 
squared ≤7.23 kg/m2 in 
men and ≤ 5.67 kg/m2 
in women)











A lean appendicular 
mass relative to height 
squared (<2 SD below 
the mean of healthy 
young adults, aged 
20–30 years)
None Walking speed 
≤1 m/s
Table 1. 
Diagnostic criteria for sarcopenia from various international societies.
Background and Management of Muscular Atrophy
6
mineral, and fat-free body mass. The disadvantages of this technique are that the 
tools used are not portable [28]. While anthropometric measurements are very easy 
to do, it is not recommended to diagnose sarcopenia because it has a very high error 
rate. Anthropometric measurements are performed by measuring the circumfer-
ence of the upper arm (LLA) or the circumference of the calf [27, 29]. Measurement 
of muscle mass is made using bio-impedance analysis (BIA), which is chosen for 
both research and clinical practice. Measurement using BIA has a good correlation 
value with MRI measurement in measuring body fat mass and body fat-free mass. 







Muscle strength Grip strength tests
• Man <26 kg
• Woman <18 kg
Physical performance Walking speed <0.8 m/s
Table 2. 
Measurement of sarcopenia according to the Asian working Group for Sarcopenia [8].
Figure 2. 
Sarcopenia diagnosis algorithm based on the Asian working Group for Sarcopenia [8].
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The most ideal muscle mass calculation for sarcopenia is based on the skeletal mass 
index (SMI), which is formulated by the appendicular skeletal mass (in kg) divided 
by height (in m2). If there is a decrease in two deviations of muscle mass index/skel-
etal mass index (SMI) from the mean SMI population of young men and women, 
then it can be categorized as a decrease in muscle mass [7].
5.2 Muscle strength
Muscle strength can be measured in several ways, namely the grip strength test, 
knee extension test, and peak expiratory flow (PEF). The grip strength test is a 
simple examination so it is both used for clinical practice and research. Studies show 
this examination has a good correlation with inferior limb strength, mobility, and 
daily living activities (ADL). Examination of the knee extension is as good as a grip 
strength test, but this examination requires equipment and training in advance so it 
is not good for clinical practice. In peak expiratory flow (PEF) tests, it is very good 
for measuring respiratory muscle strength but cannot be used to measure the overall 
muscle strength [7]. The criterion for decreasing muscle strength according to the 
AWGS is less than 20 percentile of the mean population of grip strength tests [8].
5.3 Physical performance
An examination of physical performance is an examination of muscle func-
tion by performing physical activity. There are several ways of checking physical 
performance, such as the Short Physical Performance Battery (SPPB), walking 
speed, a 6-min walk test, time up and go test, and the strength of climbing stairs. 
Inspection with Short Physical Performance Battery (SPPB) is a standard inspec-
tion for physical performance. This check is carried out to evaluate balance, path, 
strength, and endurance. SPPB is done by assessing the ability to stand on both legs, 
in semi-tandem and tandem positions, the time needed to walk 8 ft, and the time 
No Component Question Answer
1 S = Strength How difficult it is for the patient to 
lift or carry objects weighing 5 kg?
0 = No difficulties
1 = A little difficult




How difficult is it for sufferers to 




2 = Very difficult, need help, 
or cannot do without help
3 R = Rise from a chair How difficult it is for the sufferer 




2 = Very difficult, need help, 
or cannot do without help




2 = Very difficult or cannot do 
without help
5 F = Falls How many times has the patient 
fallen in the past year?
0 = Not dropped in the past year
1 = Fell 1–3 times in the past year
2 = Fell 4 times in the past year
Table 3. 
Strength, assistance walking, rise from a chair, climb stairs, and falls [34].
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needed to get up from a seat and get back to sitting for as much as five cycles [30]. 
Based on AWGS recommendations, physical performance can be measured by a test 
of running as far as 5 m. Walking speed provides predictive value for the condition 
of disability and predicts the course of the disease [31, 32]. Time to get up and go 
test is a method of measuring physical performance in the elderly by using subjects 
rising from a chair, walking at a close range, returning, and sitting as before [33]. 
Stair climb power test is used as a method for assessing foot impairment. But the 
stair climb power test is only used for research [7].
Currently, there is a questionnaire for Strength, Assistance walking, Rise from a 
chair, Climb stairs, and Falls (SARC-F), which can be used to detect early sarcope-
nia quickly and it has high specifications. This is because the diagnosis of sarcopenia 
using the SARC-F questionnaire does not require certain other measurement tools. 
This criterion is subjective only by conducting careful and thorough interviews. 
The SARC-F questionnaire has a good specificity and sensitivity in identifying the 
presence of sarcopenia. The sarcopenia category is defined if the SARCF score > 4, 
as shown in Table 3 [34].
6. Category and stage sarcopenia
Sarcopenia is a condition with many different causes and outcomes. In some 
individuals, a single cause of sarcopenia can be identified, but in other cases, 
clinicians can fail to identify the cause of sarcopenia. To facilitate clinical practice, 
sarcopenia is categorized into primary and secondary sarcopenia (Table 4). The 
etiology of sarcopenia can be multifactorial in the elderly, so there is a possibility 
that a person belongs to the primary, secondary, or both types of sarcopenia [7].
Sarcopenia stage is divided into three types based on the condition of muscle 




No other cause evident except aging
Secondary sarcopenia
• Activity-related sarcopenia
Can result from bed rest, sedentary lifestyle, deconditioning,  
or zero-gravity conditions
• Disease-related sarcopenia Associated with advanced organ failure (heart, lung, liver, kidney, 
and brain), inflammatory disease, malignancy, or endocrine disease
• Nutrition-related sarcopenia Results from inadequate dietary intake of energy and/or protein, as 
with malabsorption, gastrointestinal disorders, or use of medications 
that cause anorexia
Table 4. 
Category of sarcopenia by cause [7].
Stage Muscle mass Muscle strength Performance
Presarcopenia Decreased
Sarcopenia Decreased Decreased or normal Decreased or normal
Severe sarcopenia Decreased Decreased Decreased
Table 5. 
Stage of sarcopenia [7].
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7. Management of sarcopenia
Sarcopenia is a condition caused by a variety of complex factors. Therefore, a 
Geriatric Patient Full Assessment (P3G) for the management of sarcopenia should 
be carried out interdisciplinary with a focused and comprehensive intervention. 
P3G aims to improve physical and psychological patients, optimize drug admin-
istration to reduce the incidence of hospitalization and the risk of mortality, and 
increase patient satisfaction. P3G is carried out with an interdisciplinary team 
consisting of geriatric doctors, nurses, social workers, pharmacists, and physio-
therapists who make plans for integrated care [17].
Diet control and physical training such as resistance training and stretching have 
a positive impact on sarcopenia associated with chronic diseases such as diabetes 
mellitus, hypertension, and coronary heart disease. Besides, psychological sup-
portive therapy is needed for the management of sarcopenia because psychological 
factors of patients with sarcopenia are important in both prevention and recovery. 
Here are some recommendations for the management of sarcopenia [35]:
a. Multimodal therapy can be carried out with balanced energy and protein 
supplementation for the prevention and recovery of sarcopenia. The recom-
mended total protein intake is 1–1.5 g/kg/day.
b. The recommended protein consumption is of good quality such as the amino 
acid leucine.
c. Creatine supplementation to enhance the physical exercise effects of sarcope-
nia patients.
d. Vitamin D supplementation with doses above 100 nmol/L. A dose of vitamin D 
is given up to 50,000 IU per week.
e. Resistance and aerobic exercise are done for 20–30 min, 3 times a week.
A protein diet is an important key needed to prevent a progressive reduction in 
muscle mass. Its mechanism of action is by preventing a negative nitrogen balance. 
The recommended diet for healthy people is 0.8 g/kg/day (RDA =  recommended 
diet allowance). In the elderly >70 years, 40% of the protein diet is less than the 
RDA. In elderly patients with sarcopenia, the minimum recommended diet is 
according to the RDA (0.8) and will be increased to 1–1.5 g/kg/day by the increase 
in physical activity and comorbidities. Adequate protein intake in the elderly 
over 70 years has a positive effect on the ability to maintain muscle reserves and 
prevent sarcopenia. The positive effect is because the protein diet stimulates 
insulin-like growth factor 1 (IGF-1). Increased levels of IGF-1 as a result of this 
diet have an impact on preventing decreased protein synthesis and decreased 
muscle mass [36].
The use of creatine as a treatment for sarcopenia is still controversial because 
several studies have different results. In one study, the results showed that the 
elderly who took creatine supplements followed by endurance training experienced 
an increased muscle mass and strength. However, other studies show conflict-
ing results, where creatine supplementation does not affect the muscle mass and 
strength [37].
Vitamin D levels can affect the incidence of sarcopenia. Some data show that 
inadequate levels of vitamin D can reduce muscle function and are associated with 
Background and Management of Muscular Atrophy
10
sarcopenia. Low levels of 25 (OH) D are associated with lower muscle mass, lower 
functional test results and can be used to predict muscle mass loss which will be 
one of the causes of disability. Lack of vitamin D is associated with poorer muscle 
function and loss of muscle mass [17].
Important physical activity becomes a pillar of conventional management that is 
very profitable. Large observational studies such as the British Regional Heart Study 
(BRHS), the Third National Health and Nutrition Examination Survey (NHANES 
III), and the Cardiovascular Health Study (CHS) show an inverse relationship 
between CRP concentration and physical activity in the elderly. The Health Aging 
and Body Composition (Health ABC) Study also found a linear tendency to 
decrease TNF with increased physical activity [9]. Therefore, physical activity is 
very necessary for the management of sarcopenia. The management of sarcopenia 
through physical activity must be designed with specific guidelines so that it gradu-
ally burdens muscles and makes positive adaptations. This should also be noted in 
physiology related to age and aging to avoid injury. Physical exercise in sarcopenia 
patients is focused on dynamic movements that target the major or major muscle 
groups such as knee and hip extensors through intrinsic and eccentric movements. 
The period of heating and cooling in the elderly is sought to last 15–20 min when 
heating and 10–15 min when cooling [38].
Management of other sarcopenia is still under studies, such as the therapeutic 
approach of using testosterone, estrogen, dehydroepiandrosterone (DHEA), and 
angiotensin-converting enzyme inhibitors (ACE inhibitors) [17].
8. Conclusions
Sarcopenia is more prevalent in older patients, especially men, and is defined 
by decreased muscle mass with decreased muscle strength and/or performance. 
Sarcopenia can cause multiple morbidities in the elderly, including frailty, fractures, 
falls, and even death. There are multifactorial factors (divided into intrinsic and 
extrinsic factors) that trigger sarcopenia, but the inflammatory process is recog-
nized as a basic mechanism. Constitutional factors, aging, lifestyle, changes in body 
condition, and chronic diseases are considered as risk factors for sarcopenia in the 
elderly. Diagnostic criteria for sarcopenia are still under controversy since there 
is a variety of the component because it differs based on race and gender. Criteria 
from EWGSOP and AWGS are the most widely used. Currently, SARC-F question-
naires can detect early sarcopenia and have high specifications. In clinical practice, 
sarcopenia is categorized into primary and secondary sarcopenia and is divided 
into three stadiums, which are pre-sarcopenia, sarcopenia, and severe sarcopenia. 
Management of sarcopenia should be interdisciplinary with a focused and com-
prehensive intervention. Nutrition and physical training are the most important 
therapies for sarcopenia in the elderly.
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